Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Spray shows promise for non-healing foot ulcers

  • 1 Comment

A novel treatment involving oxygen therapy has shown promise in a small study of UK patients with non-healing diabetic foot ulceration.

The study showed diabetic foot ulcers treated with Granulox demonstrated significantly better and more rapid wound closure than standard care.

“Diabetic foot ulcers have a significant impact on a patient’s quality of life and place patients at higher risk for lower limb amputations”

Sharon Bateman

Granulox is topical haemoglobin spray treatment for chronic wounds, which was launched in England, Wales and Scotland in 2014.

The active haemoglobin is intended to improve the oxygen supply to the wound by aiding diffusion of oxygen into its base and, as a result, accelerate healing.

The study – the UK’s largest to date on the technology – was conducted by South Tees NHS Hospitals Foundation.

It included 20 adult patients with non-healing diabetic foot ulcers located beneath the ankle. Of the 20 patients in the study, seven had type 1 diabetes and the remaining 13 had type 2.

After four weeks, all trial patients reported a reduction in wound surface area, elimination of slough and an improvement in exudate levels.

A quarter of patients reported a 100% reduction in wound area. The average wound size reduction was 62.3%, said the researchers.

They added that even wounds that had been present for 12 months or more reduced by an average of 24% within the four weeks of the trial.

The data was presented at the recent European Wound Management Association conference and published in the British Journal of Nursing.

During the treatment with Granulox, the researchers found all patients in the trial – who previously had a wound bed slough between 10%-100% – were slough-free, with no debridement required. 

In addition, there was a significant reduction in exudate levels across all patients – a 29% reduction in wounds with mild exudate, a 86% reduction in moderate exuding wounds and a complete resolution of all six patients with severe exuding wounds.

Both the patient and clinician experience of Granulox was positive, with the treatment’s easy-to-use spray functionality hailed as a key product benefit, added the technology’s developer infirst Healthcare.

Study author Sharon Bateman, a specialist tissue viability nurse at South Tees, noted that foot ulcers put patients at a higher risk of lower limb amputations as well as placing a significant burden on NHS resources.

She suggested the new oxygen therapy had the potential to boost self-management of foot ulcers among diabetes patients.  

“Aside from the clinical benefits seen in the trial, 75% of patients were able to apply Granulox independently, making the prospect of patients managing their diabetic foot ulcer independently or with the help of their healthcare team a distinct reality,” she said.

  • 1 Comment

Readers' comments (1)

  • Would this be suitable I wonder for non diabetic patients too ??

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs